Literature DB >> 18799708

Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification.

Johannes Vermehren1, Annika Kau, Barbara C Gärtner, Reinhild Göbel, Stefan Zeuzem, Christoph Sarrazin.   

Abstract

Hepatitis C virus (HCV) RNA detection and quantification are the key diagnostic tools for the management of hepatitis C. Commercially available HCV RNA assays are calibrated to the HCV genotype 1 (gt1)-based WHO standard. Significant differences between assays have been reported. However, it is unknown which assay matches the WHO standard best, and little is known about the sensitivity and linear quantification of the assays for non-gt1 specimens. Two real-time reverse transcriptase PCR-based assays (RealTime HCV and Cobas Ampliprep/Cobas TaqMan HCV [CAP/CTM]) and one signal amplification-based assay (the Versant HCV RNA, version 3.0, branched DNA [bDNA] assay) were compared for their abilities to quantify HCV RNA in clinical specimens (n = 65) harboring HCV isolates of gt1 to g5. The mean differences in the amounts detected by RealTime HCV in comparison to those detected by the bDNA assay and CAP/CTM were -0.02 and 0.72 log(10) IU/ml HCV RNA, respectively, for gt1; -0.22 and 0.03 log(10) IU/ml HCV RNA, respectively, for gt2; -0.27 and -0.22 log(10) IU/ml HCV RNA, respectively, for gt3; -0.19 and -1.27 log(10) IU/ml HCV RNA, respectively, for gt4; and -0.03 and 0.09 log(10) IU/ml HCV RNA, respectively, for gt5. The lower limits of detection for RealTime HCV and CAP/CTM were 16.8 and 10.3 IU/ml, respectively, for the WHO standard and in the range of 4.7 to 9.0 and 3.4 to 44.4 IU/ml, respectively, for clinical specimens harboring gt1 to gt6. Direct comparison of the two assays with samples of the WHO standard (code 96/798) with high titers yielded slightly smaller amounts by RealTime HCV (-0.2 log(10) at 1,500 IU/ml and -0.3 log(10) at 25,000 IU/ml) and larger amounts by CAP/CTM (0.3 log(10) at 1,500 IU/ml and 0.2 log(10) at 25,000 IU/ml). Finally, all three tests were linear between 4.0 x 10(3) and 1.0 x 10(6) IU/ml (correlation coefficient, >or=0.99). In conclusion, the real-time PCR based assays sensitively detected all genotypes and showed comparable linearities for the quantification of HCV RNA, with the exception of gt1 and gt4. The previously reported differences in the absolute quantification of samples harboring gt1 were confirmed and may be explained by different calibrations to the WHO standard.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18799708      PMCID: PMC2593291          DOI: 10.1128/JCM.00755-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  27 in total

1.  Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques.

Authors:  J Saldanha; N Lelie; M W Yu; A Heath
Journal:  Vox Sang       Date:  2002-01       Impact factor: 2.144

2.  Highly sensitive hepatitis C virus RNA detection assays for decision of treatment (dis)continuation in patients with chronic hepatitis C.

Authors:  Ulrike Mihm; Wolf-Peter Hofmann; Bernd Kronenberger; Michael von Wagner; Stefan Zeuzem; Christoph Sarrazin
Journal:  J Hepatol       Date:  2004-11-26       Impact factor: 25.083

3.  Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

Authors:  Peter Ferenci; Michael W Fried; Mitchell L Shiffman; Coleman I Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampero Carosi; Daniel Dhumeaux; Antonio Craxì; Monique Chaneac; K Rajender Reddy
Journal:  J Hepatol       Date:  2005-09       Impact factor: 25.083

4.  Subtyping of hepatitis C virus isolates by a line probe assay using hybridization.

Authors:  A Andonov; R K Chaudhary
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

5.  Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay.

Authors:  R S Ross; S Viazov; S Sarr; S Hoffmann; A Kramer; M Roggendorf
Journal:  J Virol Methods       Date:  2002-03       Impact factor: 2.014

6.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

7.  World Health Organization collaborative study to establish a replacement WHO international standard for hepatitis C virus RNA nucleic acid amplification technology assays.

Authors:  J Saldanha; A Heath; C Aberham; J Albrecht; G Gentili; M Gessner; G Pisani
Journal:  Vox Sang       Date:  2005-04       Impact factor: 2.144

8.  Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

Authors:  Gary L Davis; John B Wong; John G McHutchison; Michael P Manns; Joann Harvey; Janice Albrecht
Journal:  Hepatology       Date:  2003-09       Impact factor: 17.425

9.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

10.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

View more
  35 in total

1.  Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors.

Authors:  F Wiesmann; G Naeth; C Sarrazin; A Berger; R Kaiser; R Ehret; H Knechten; P Braun
Journal:  Med Microbiol Immunol       Date:  2014-11-15       Impact factor: 3.402

2.  Alterations in immune function are associated with liver enzyme elevation in HIV and HCV co-infection after commencement of combination antiretroviral therapy.

Authors:  Barbara Anne Cameron; Carol R Emerson; Cassy Workman; Mark D Kelly; Andrew R Lloyd; Jeffrey J Post
Journal:  J Clin Immunol       Date:  2011-09-20       Impact factor: 8.317

3.  Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity.

Authors:  Johannes Vermehren; Giuseppe Colucci; Peter Gohl; Nabila Hamdi; Ahmed Ihab Abdelaziz; Ursula Karey; Diana Thamke; Heike Zitzer; Stefan Zeuzem; Christoph Sarrazin
Journal:  J Clin Microbiol       Date:  2011-07-13       Impact factor: 5.948

4.  European Multicenter Study on Analytical Performance of DxN Veris System HCV Assay.

Authors:  Patrick Braun; Rafael Delgado; Monica Drago; Diana Fanti; Hervé Fleury; Maria Rita Gismondo; Jörg Hofmann; Jacques Izopet; Sebastian Kühn; Alessandra Lombardi; Maria Angeles Marcos; Karine Sauné; Siobhan O'Shea; Alfredo Pérez-Rivilla; John Ramble; Pascale Trimoulet; Jordi Vila; Duncan Whittaker; Alain Artus; Daniel W Rhodes
Journal:  J Clin Microbiol       Date:  2017-02-01       Impact factor: 5.948

Review 5.  Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease.

Authors:  Mahrukh Akbar Shaheen; Muhammad Idrees
Journal:  World J Hepatol       Date:  2015-03-27

6.  A case-control study of factors associated with resolution of hepatitis C viremia in former blood donors (CME).

Authors:  Leslie H Tobler; Shrein H Bahrami; Zhanna Kaidarova; Lubov Pitina; Valarie K Winkelman; Sandra K Vanderpool; Anne M Guiltinan; Stewart Cooper; Michael P Busch; Edward L Murphy
Journal:  Transfusion       Date:  2010-03-25       Impact factor: 3.157

Review 7.  Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.

Authors:  Eleanor M Wilson; Elana S Rosenthal; Sarah Kattakuzhy; Lydia Tang; Shyam Kottilil
Journal:  Clin Microbiol Rev       Date:  2016-10-19       Impact factor: 26.132

8.  Performance of the Abbott RealTime and Roche Cobas TaqMan hepatitis C virus (HCV) assays for quantification of HCV genotypes.

Authors:  Heidi LaRue; Lisa Rigali; Joan-Miquel Balada-Llasat; Preeti Pancholi
Journal:  J Clin Microbiol       Date:  2012-02-29       Impact factor: 5.948

Review 9.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

10.  Evaluation of the Abbott investigational use only RealTime hepatitis C virus (HCV) assay and comparison to the Roche TaqMan HCV analyte-specific reagent assay.

Authors:  Michael T Pyne; Eric Q Konnick; Amit Phansalkar; David R Hillyard
Journal:  J Clin Microbiol       Date:  2009-07-22       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.